Less Than 95% Adherence to Nonnucleoside Reverse‐Transcriptase Inhibitor Therapy Can Lead to Viral Suppression
DOI: 10.1086/507526
关键词: Oncology 、 Extramural 、 Reverse-transcriptase inhibitor 、 Antiretroviral therapy 、 Lead (electronics) 、 Viral suppression 、 Pill 、 Medicine 、 Protease inhibitor (pharmacology) 、 Medication monitoring 、 Immunology 、 Internal medicine
摘要: For antiretroviral therapy, the 95% adherence "threshold" is based on nucloside-exposed patients who are receiving partially suppressive, unboosted protease inhibitor regimens. Using unannounced pill counts and electronic medication monitoring, viral suppression common with a 54%-100% mean level to nonnucleoside reverse-transcriptase-inhibitor Although perfect an important goal, possible moderate potent
oup.com
paperity.org
oxfordjournals.org参考文章(18)
Mitchell D. Wong, , William E. Cunningham, Martin F. Shapiro, Ronald M. Andersen, Paul D. Cleary, Naihua Duan, Hong Hu Liu, Ira B. Wilson, Bruce E. Landon, Neil S. Wenger, Disparities in HIV treatment and physician attitudes about delaying protease inhibitors for nonadherent patients. Journal of General Internal Medicine. ,vol. 19, pp. 366- 374 ,(2004) , 10.1111/J.1525-1497.2004.30429.X
David R. Bangsberg, Frederick M. Hecht, Edwin D. Charlebois, Andrew R. Zolopa, Mark Holodniy, Lewis Sheiner, Joshua D. Bamberger, Margaret A. Chesney, Andrew Moss, Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. ,vol. 14, pp. 357- 366 ,(2000) , 10.1097/00002030-200003100-00008
Patricia García de Olalla, Hernando Knobel, Alexia Carmona, Ana Guelar, José L. López-Colomés, Joan A. Caylà, Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes. ,vol. 30, pp. 105- 110 ,(2002) , 10.1097/00042560-200205010-00014
David R. Bangsberg, Steven G. Deeks, Is average adherence to HIV antiretroviral therapy enough Journal of General Internal Medicine. ,vol. 17, pp. 812- 813 ,(2002) , 10.1046/J.1525-1497.2002.20812.X
David R Bangsberg, Edward P Acosta, Reena Gupta, David Guzman, Elise D Riley, P Richard Harrigan, Neil Parkin, Steven G Deeks, Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS. ,vol. 20, pp. 223- 231 ,(2006) , 10.1097/01.AIDS.0000199825.34241.49
David R. Bangsberg, Sharon Perry, Edwin D. Charlebois, Richard A. Clark, Marjorie Roberston, Andrew R. Zolopa, Andrew Moss, Non-adherence to highly active antiretroviral therapy predicts progression to Aids AIDS. ,vol. 15, pp. 1181- 1183 ,(2001) , 10.1097/00002030-200106150-00015
P. Richard Harrigan, Robert S. Hogg, Winnie W. Y. Dong, Benita Yip, Brian Wynhoven, Justin Woodward, Chanson J. Brumme, Zabrina L. Brumme, Theresa Mo, Chris S. Alexander, Julio S. G. Montaner, Predictors of HIV Drug-Resistance Mutations in a Large Antiretroviral-Naive Cohort Initiating Triple Antiretroviral Therapy The Journal of Infectious Diseases. ,vol. 191, pp. 339- 347 ,(2005) , 10.1086/427192
David R Bangsberg, Edwin D Charlebois, Robert M Grant, Mark Holodniy, Steven G Deeks, Sharon Perry, Kathleen Nugent Conroy, Richard Clark, David Guzman, Andrew Zolopa, Andrew Moss, High levels of adherence do not prevent accumulation of HIV drug resistance mutations AIDS. ,vol. 17, pp. 1925- 1932 ,(2003) , 10.1097/00002030-200309050-00011
Catia Marzolini, Amalio Telenti, Laurent A. Decosterd, Gilbert Greub, Jérôme Biollaz, Thierry Buclin, Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. ,vol. 15, pp. 71- 75 ,(2001) , 10.1097/00002030-200101050-00011
A. R. Moss, J. A. Hahn, S. Perry, E. D. Charlebois, D. Guzman, R. A. Clark, D. R. Bangsberg, Adherence to Highly Active Antiretroviral Therapy in the Homeless Population in San Francisco: A Prospective Study Clinical Infectious Diseases. ,vol. 39, pp. 1190- 1198 ,(2004) , 10.1086/424008